Alan Hauser is an accomplished life sciences commercialization leader having translated proprietary innovations from the...
Alan K. Hauser, Ph.D. Telephone: 847-721-1200 E-Mail:
[email protected]
Deerfield, IL 60015
SUMMARY OF QUALIFICATIONS Accomplished life sciences commercialization leader having translated proprietary innovations from the bench to the marketplace via new venture creation and licensing Strong technical/IP assessment capabilities; formidable product roadmapping acumen Certified Licensing ProfessionalTM; demonstrated ability to value and drive deals
For 15 years, have helped build businesses based on disruptive biotechnologies that are transforming the way research and medicine is practiced, including: – Commercialized FDA-cleared, microarray-enabled DNA diagnostics products – Developed and managed a broad microfluidics patent portfolio for a venture-backed bioscience company that resulted in its $189 million IPO EXPERIENCE Northwestern University, Evanston and Chicago, IL 2008 2011 Executive Director of Technology Licensing and Business Development NU Innovation and New Ventures Office (INVO), formerly known as NU TTP 2010 2011 Managed Technology Licensing Team (6 professionals and 40 interns) responsible for: Evaluating approximately 200 invention disclosures per year Overseeing 30 executed and 20 pending license agreements this year Licensing revenue in excess of $150 million per year for the past 3 years
Director of Business Development, NU Technology Transfer Program (TTP)
2008 2010
Bridged the gap between NU research and its practical use for public benefit Marketed in excess of 150 technologies/patent portfolios Led structuring and negotiating of 20 license/option agreements Built/nurtured culture of innovation, including 40 NUCo startups, which raised $199 million in venture/corporate investment this year (2010-2011)
Bio-Com International, Deerfield, IL Managing Director of biosciences commercial development consultancy committed to
2011 present 2004 2008
assisting companies create value by enhancing and sustaining their competitive advantage 4
Developed Bio-Com’s Bio-Biz Builder (B U)SM strategy, IP appraisal, technology / product roadmapping, and financial frameworks to forecast varying market scenarios Helped fuel clients’ innovation growth engine that will enable future profitability Developed compelling strategic plans for high-impact market expansion opportunities based on forward-looking intelligence and valuation analytics Exploited commercial potential of emerging bio-detection technology more broadly so when realized will quadruple public company’s annual gross profit Assessed competitive IP landscape and marketability of emerging biotechnologies
Clinical Micro Sensors, a Motorola Company sold to Osmetech plc, GenMark Dx Sr. Business Development Manager of biochip business unit based in Pasadena, CA Secured commercial IP rights for eSensorTM molecular diagnostics platform Led strategic roadmapping to assess ‘build-vs.-buy’ opportunities by linking technology/IP to product functionality driven by customer’s value proposition and demand as determined by my competitive market intelligence and research Invited speaker on bio-nano convergence commercialization in U.S., Japan, Israel, China Negotiated royalty reductions up to 95% enabling multi-million-dollar cost savings by employing profitability analysis and my weighted-contribution royalty structure
2002 2004
Alan K. Hauser, Ph.D. Motorola Life Sciences sold to Amersham Biosciences, GE Healthcare, Surmodics 1999 2002 Business and Strategy Development Sr. Manager of biotools business unit in Northbrook, IL Identified and assessed new opportunities and executed licenses in support of launch of CodeLinkTM gene expression and SNP genotyping microarray products Created, developed and implemented market-development initiative for Massively-Parallel, Multi-Plexed Genomics (MPGx) commercial offering Received Motorola BRAVO! Leadership Award for championing MPGx program Directed commercial aspects of MLS' exploratory proteomics initiative Conducted biotech-business and IP due-diligence for Motorola Ventures
ACLARA BioSciences, sold to Monogram Biosciences, A LabCorp Company Intellectual Property and Licensing Director of Bay Area lab-on-a-chip venture
1997 1999
Managed and built broad IP portfolio from ~10 U.S. patents and applications to more than 130 pending and issued U.S. patents plus hundreds worldwide enabling $189 M IPO Co-invented microfluidic methods for drug screening/genetic analyses that resulted in 4 U.S. patents and more than a dozen pending applications/foreign equivalents Developed and employed freedom-to-operate and strategic market landscaping tools for visualizing and analyzing competitive technology-IP (TIP) space and new product offerings Prepared and presented TIP marketing materials that led to 3 major corporate partnerships
Pangene Corporation, sold to NaPro BioTherapeutics, Tapestry Pharmaceuticals 1995 1996 Business Development Director of Bay Area biotechnology tools and services venture Consummated licenses to DNA recombination methods for transgenesis, therapy and diagnostics Refocused business plan and spearheaded marketing efforts leading to 1st corporate collaboration
SRI International (formerly Stanford Research Institute), Menlo Park, CA 1992 1995 Technology Assessment and Marketing Consultant, at Contract Research Organization Evaluated commercial potential of emerging biotechnologies for Business Intelligence Center Conducted and managed client-funded feasibility investigations in Science & Technology Group
EDUCATION Professional business training and development Executive Program in Business Admin., Kellogg Management Institute, Northwestern University Executive Finance Programs: Valuation and Corporate Venture Capital, Harvard Business School MBA Courses: Technology Strategy, Corporate Finance, Private Equity and Entrepreneurial Finance, Booth School of Business, University of Chicago
Postdoctoral Fellow, Hawaii Biosensor Lab, Dept. of Chemistry, University of Hawaii, Honolulu Co-wrote successful NIH grant proposal that resulted in funding to develop miniaturized molecular-recognition sensors and assays for pharmaceutical drug discovery and development Postdoctoral Fellow, Dept. of Chemical Engineering and Chemistry, University of Texas, Austin Optimized microfabricated biosensors, which became basis for Dx venture acquired for $1.2 billion
Ph.D. Chemical Engineering, College of Chemistry, University of California, Berkeley Developed and characterized analytical detection method having diagnostics applications
Page 2 of 2
